Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Feb;20(2):e202200807.
doi: 10.1002/cbdv.202200807. Epub 2023 Jan 11.

Synthetic Naphthoquinone Derivatives as Anticancer Agents in Ovarian Cancer: Cytotoxicity Assay and Investigation of Possible Biological Mechanisms Action

Affiliations

Synthetic Naphthoquinone Derivatives as Anticancer Agents in Ovarian Cancer: Cytotoxicity Assay and Investigation of Possible Biological Mechanisms Action

Renata Dalmaschio Daltoé et al. Chem Biodivers. 2023 Feb.

Abstract

In this study, eight naphthoquinone derivatives were synthesized in yields ranging from 52 to 96% using easy, fast, and low-cost methodologies. All naphthoquinone derivatives were screened for their in vitro anti-proliferative activities against OVCA A2780 cancer cell lines. Amongst all analysed compounds, derivatives 3-5 presented the most prominent cytotoxic potential. Naphthoquinones 3 and 4, bearing sulfur-containing groups, were identified as having high potential for ROS production, in particular the superoxide anion. Furthermore, 3 and 4 compounds caused a decrease in the cell population in G0/G1 and induced more than 90% of the cell population to apoptosis. Compound 5 did not act in any of these processes. Finally, compounds 3-5 were tested for their inhibitory ability against PI3K and MAPK. Compounds 3 and 4 do not inhibit the PI3K enzyme. On the other hand, the naphthoquinone-polyphenol 5 was only able to inhibit the percentage of cells expressing pERK.

Keywords: anticancer activity; naphthoquinone; ovarian cancer.

PubMed Disclaimer

References

    1. K. D. Miller, L. Nogueira, T. Devasia, A. B. Mariotto, K. R. Yabroff, A. Jemal, J. Kramer, R. L. Siegel, ‘Cancer treatment and survivorship statistics, 2022’, Ca-Cancer J. Clin. 2022, 72, 409-436.
    1. R. J. Kurman, I. M. Shih, ‘Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer - Shifting the paradigm’, Hum. Pathol. 2011, 42, 918-931.
    1. B. Radl, B. Mlineritsch, ‘ASCO 2017 - highlights of gynecological cancer’, Memo 2017, 10, 237-239.
    1. A. V. Pinto, S. L. De Castro, ‘The Trypanocidal Activity of Naphthoquinones: A Review’, Molecules 2009, 14, 4570-4590.
    1. M. Manickam, P. R. Boggu, T. Pillaiyar, Y. J. Nam, M. Abdullah, S. J. Lee, J. S. Kang, S. H. Jung, ‘Design, synthesis and anticancer activity of 2-amidomethoxy-1,4-naphthoquinones and its conjugates with Biotin/Polyamine’, Bioorg. Med. Chem. Lett. 2021, 31, 127685.

LinkOut - more resources